Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report

Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report

Introduction: Chronic myeloid leukemia (CML) is characterized by the presence of the BCR::ABL1 fusion gene, and the advent of tyrosine kinase inhibitors (TKIs) has revolutionized its therapeutic landscape. Asciminib, a STAMP inhibitor, emerges as a promising option for patients unresponsive or intol...

Full description

Bibliographic Details
Main Authors:	Awni Alshurafa, Afshan Adil, Mohamed A. Yassin
Format:	Article
Language:	English
Published:	Karger Publishers 2024-01-01
Series:	Case Reports in Oncology
Subjects:	chronic kidney disease asciminib deep molecular response bcr::abl1 chronic myeloid leukemia
Online Access:	https://beta.karger.com/Article/FullText/535958

Similar Items

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
by: Valentin Garcia-Gutierrez, et al.
Published: (2024-11-01)

Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation
by: A. G. Turkina, et al.
Published: (2024-12-01)

Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance
by: Naoki Okamoto, et al.
Published: (2024-08-01)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
by: Junichiro Yuda, et al.
Published: (2023-02-01)

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
by: Hijiya N, et al.
Published: (2023-08-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

Coexistence of P190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis: a case report
by: najmaldin saki, et al.
Published: (2016-01-01)

Pleural effusion as the presenting feature in chronic myeloid leukemia
by: Archana S Bhat, et al.
Published: (2023-01-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Efficacy and safety of switching to flumatinib in patients with chronic myeloid leukemia who have not achieved optimal response or are intolerant to TKI treatment
by: YANG Songfan, et al.
Published: (2024-02-01)

Pediatric chronic myeloid leukemia in myeloid blast crisis
by: Biswajit Dey, et al.
Published: (2023-04-01)

Hematological profile and its correlation with reverse transcription–polymerase chain reaction-based serial quantitative detection of BCR-ABL in chronic myeloid leukemia patients at a referral cancer center
by: Vanita Pandey, et al.
Published: (2024-12-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Fluorescent in-situ hybridization (FISH) for BCR/ABL in chronic myeloid leukemia after bone marrow transplantation
by: Maria de Lourdes Lopes Ferrari Chauffaille, et al.
Published: (2001-01-01)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022-01-01)

Autophagy and Cancer: Insights into Molecular Mechanisms and Therapeutic Approaches for Chronic Myeloid Leukemia
by: Mohd Adnan Kausar, et al.
Published: (2025-02-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

The Relationship Between Bcr-Abl1 Related MicroRNA's Expression Levels And Imatinib Resistance In Chronic Myeloid Leukemia Cases
by: Omer Yakar, et al.
Published: (2024-10-01)

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
by: Sarah Tomassetti, et al.
Published: (2022-11-01)

A Case of Hepatocellular Carcinoma after Treatment for Chronic Myeloid Leukemia in a Patient without Liver Disease
by: Darshankumar M. Raval, et al.
Published: (2024-07-01)

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
by: Alejandro Zulbaran‐Rojas, et al.
Published: (2018-11-01)

The comparative analysis of BCR-ABL/ABL detection by real-time quantitative PCR and automated GeneXpert Dx System in chronic myeloid leukemia patients with major and complete molecular response
by: S. A. Smirnikhina, et al.
Published: (2014-07-01)

Nuclear-cytoplasmic Shuttling in Chronic Myeloid Leukemia: Implications in Leukemia Maintenance and Therapy
by: Giovanna Carrà, et al.
Published: (2019-10-01)

Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
by: Stefania Stella, et al.
Published: (2022-04-01)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01)

Subclinical Hypothyroidism Following Imatinib Use in Nigerian BCR::ABL1-positive Chronic Myeloid Leukemia Patients: A Prospective Cohort Study
by: Ibrahim Oluwaseun Ahmed, et al.
Published: (2024-09-01)

Novel targeted therapies in chronic myeloid leukemia
by: Muhammad Sameer Ashaq, et al.
Published: (2024-12-01)

A review on characterization of BCR – ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes
by: Benyam Zenebe, et al.
Published: (2023-12-01)

Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study
by: Manar Mohamd Mohamad Ismail, et al.
Published: (2013-12-01)

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
by: Carla Boquimpani, et al.
Published: (2022-07-01)

Chronic myeloid leukemia in an asymptomatic young patient: a rare case report
by: Urja Bhatt, et al.
Published: (2024-11-01)

PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)
by: Huamin Liang, et al.
Published: (2022-08-01)

Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia
by: Vera Vysochinskaya, et al.
Published: (2024-05-01)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023-12-01)

The comparative analysis of BCR-ABL/ABL detection by real-time quantitative PCR and automated GeneXpert Dx System in chronic myeloid leukemia patients with major and complete molecular response
by: S. A. Smirnikhina, et al.
Published: (2014-07-01)

Apoptosis resistance in chronic myelogenous leukemia
by: Fabíola Attié de Castro, et al.
Published: (2005-09-01)

circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation
by: Jianming Wang, et al.
Published: (2022-09-01)

Artificial Intelligence Assisted Pharmacophore Design for Philadelphia Chromosome-Positive Leukemia with Gamma-Tocotrienol: A Toxicity Comparison Approach with Asciminib
by: Muhammad Naveed, et al.
Published: (2023-03-01)

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?
by: Francesco Tarantini, et al.
Published: (2022-12-01)